Literature DB >> 34437109

Scent of a vaccine.

Frances E Lund1, Troy D Randall2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34437109     DOI： 10.1126/science.abg9857

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  22 in total

1.  Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine.

Authors:  Zhenzhen Wang; Kristen D Popowski; Zhenhua Li; Dashuai Zhu; Blanca López de Juan Abad; Xianyun Wang; Mengrui Liu; Halle Lutz; Nicole De Naeyer; C Todd DeMarco; Thomas N Denny; Phuong-Uyen C Dinh; Ke Cheng
Journal:  Nat Biomed Eng       Date:  2022-07-04       Impact factor: 29.234

2.  A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2.

Authors:  Junyu Chen; Pui Wang; Lunzhi Yuan; Liang Zhang; Limin Zhang; Hui Zhao; Congjie Chen; Xijing Wang; Jinle Han; Yaode Chen; Jizong Jia; Zhen Lu; Junping Hong; Zicen Lu; Qian Wang; Rirong Chen; Ruoyao Qi; Jian Ma; Min Zhou; Huan Yu; Chunlan Zhuang; Xiaohui Liu; Qiangyuan Han; Guosong Wang; Yingying Su; Quan Yuan; Tong Cheng; Ting Wu; Xiangzhong Ye; Tianying Zhang; Changgui Li; Jun Zhang; Huachen Zhu; Yixin Chen; Honglin Chen; Ningshao Xia
Journal:  Sci Bull (Beijing)       Date:  2022-05-26       Impact factor: 20.577

3.  Comparison of the Immunogenic Properties of Lactiplantibacillus plantarum Carrying the Mycobacterial Ag85B-ESAT-6 Antigen at Various Cellular Localizations.

Authors:  Kamilla Wiull; Preben Boysen; Katarzyna Kuczkowska; Lars Fredrik Moen; Harald Carlsen; Vincent G H Eijsink; Geir Mathiesen
Journal:  Front Microbiol       Date:  2022-06-03       Impact factor: 6.064

4.  Intranasal SARS-CoV-2 Vaccines: Indispensable and Inevitable.

Authors:  Eli Y Adashi; Philip A Gruppuso
Journal:  Am J Prev Med       Date:  2022-07-11       Impact factor: 6.604

Review 5.  Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern.

Authors:  Khursheed Ul Islam; Thoraya Mohamed Elhassan A-Elgadir; Sarah Afaq; Tanveer Ahmad; Jawed Iqbal
Journal:  Front Pharmacol       Date:  2021-12-23       Impact factor: 5.810

6.  An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.

Authors:  Peter A van der Ley; Afshin Zariri; Elly van Riet; Dinja Oosterhoff; Corine P Kruiswijk
Journal:  Front Immunol       Date:  2021-12-17       Impact factor: 7.561

7.  The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory.

Authors:  Sonia Ndeupen; Zhen Qin; Sonya Jacobsen; Aurélie Bouteau; Henri Estanbouli; Botond Z Igyártó
Journal:  iScience       Date:  2021-11-20

8.  Salivary antibodies are detected with a commercial anti-SARS-CoV-2 assay only after two doses of vaccine using serum thresholds.

Authors:  J L Robinson; G J German
Journal:  Clin Biochem       Date:  2022-02-04       Impact factor: 3.625

9.  Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.

Authors:  Alberto Cagigi; Meng Yu; Björn Österberg; Julia Svensson; Sara Falck-Jones; Sindhu Vangeti; Eric Åhlberg; Lida Azizmohammadi; Anna Warnqvist; Ryan Falck-Jones; Pia C Gubisch; Mert Ödemis; Farangies Ghafoor; Mona Eisele; Klara Lenart; Max Bell; Niclas Johansson; Jan Albert; Jörgen Sälde; Deleah D Pettie; Michael P Murphy; Lauren Carter; Neil P King; Sebastian Ols; Johan Normark; Clas Ahlm; Mattias N Forsell; Anna Färnert; Karin Loré; Anna Smed-Sörensen
Journal:  JCI Insight       Date:  2021-11-22

10.  Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Authors:  Min-Wen Ku; Pierre Authié; Maryline Bourgine; François Anna; Amandine Noirat; Fanny Moncoq; Benjamin Vesin; Fabien Nevo; Jodie Lopez; Philippe Souque; Catherine Blanc; Ingrid Fert; Sébastien Chardenoux; Llta Lafosse; Delphine Cussigh; David Hardy; Kirill Nemirov; Françoise Guinet; Francina Langa Vives; Laleh Majlessi; Pierre Charneau
Journal:  EMBO Mol Med       Date:  2021-10-25       Impact factor: 12.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.